NasdaqGS - Nasdaq Real Time Price • USD
Genmab A/S (GMAB)
As of 12:33 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 0.32 | 0.31 | 1.08 | 1.49 |
| Low Estimate | 0.31 | 0.3 | 1.08 | 1.44 |
| High Estimate | 0.33 | 0.33 | 1.08 | 1.54 |
| Year Ago EPS | 0.3 | 0.47 | 0.96 | 1.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 11 | 10 |
| Avg. Estimate | 720.95M | 755.4M | 2.87B | 3.47B |
| Low Estimate | 678.15M | 719.67M | 2.74B | 3.18B |
| High Estimate | 779.92M | 788.63M | 2.93B | 3.69B |
| Year Ago Sales | 613.62M | 692.39M | 2.39B | 2.87B |
| Sales Growth (year/est) | 17.50% | 9.10% | 20.10% | 20.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.18 | 3.14 | 3.25 | 0.14 |
| EPS Actual | 0.3 | 0.47 | 0.14 | 0.29 |
| Difference | -1.88 | -2.67 | -3.11 | 0.15 |
| Surprise % | -86.20% | -85.00% | -95.70% | 107.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.32 | 0.31 | 1.08 | 1.49 |
| 7 Days Ago | 0.32 | 0.31 | 1.08 | 1.49 |
| 30 Days Ago | 0.3 | 0.3 | 1.1 | 1.5 |
| 60 Days Ago | 3.77 | 3.89 | 11.51 | 18.15 |
| 90 Days Ago | 3.71 | 3.83 | 13.98 | 17.86 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GMAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6.70% | -- | -- | 8.00% |
| Next Qtr. | -34.00% | -- | -- | 12.40% |
| Current Year | 12.50% | -- | -- | 5.60% |
| Next Year | 38.00% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 13.10% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -26.66% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/30/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Maintains | Morgan Stanley: Underweight to Underweight | 3/26/2024 |
Related Tickers
ARGX argenx SE
365.38
-0.12%
BGNE BeiGene, Ltd.
172.96
+0.06%
RPRX Royalty Pharma plc
27.46
+0.68%
HALO Halozyme Therapeutics, Inc.
44.54
-0.38%
LEGN Legend Biotech Corporation
45.55
+0.86%
PCVX Vaxcyte, Inc.
75.72
+1.54%
ASND Ascendis Pharma A/S
120.92
-0.17%
BBIO BridgeBio Pharma, Inc.
29.87
-0.75%
ROIV Roivant Sciences Ltd.
11.34
+0.98%
INCY Incyte Corporation
57.16
+0.11%